X

Trial Profile

Sequential vs upfront intensified neoadjuvant chemotherapy in patients with large resectable and/or locally advanced breast cancer. The INTENS Study.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 09 Feb 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cyclophosphamide (Primary) ; Docetaxel (Primary) ; Doxorubicin (Primary)
Indications Advanced breast cancer
Focus Therapeutic Use
Acronyms INTENS

Most Recent Events

10 Jul 2013 Primary endpoint 'Complete-pathological-response-rate' has not been met.
10 Jul 2013 Results published in the European Journal of Cancer.
08 Dec 2012 Results presented at the 35th Annual San Antonio Breast Cancer Symposium.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com